<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03872362</url>
  </required_header>
  <id_info>
    <org_study_id>UM2019DLABGY1</org_study_id>
    <nct_id>NCT03872362</nct_id>
  </id_info>
  <brief_title>Radiomics Multifactorial Biomarker for Pulmonary Nodules</brief_title>
  <acronym>RMBPN</acronym>
  <official_title>Radiomics and Clinical Variables Can Differentiate Malignant Nodules and Detect Invasive Adenocarcinoma in Pulmonary Nodules: a Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Zhongshan Hospital of Dalian University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fifth Hospital of Dalian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to investigate the utility of radiomics to differentiate malignant
      nodules from benign nodules and invasive adenocarcinoma from non-invasive adenocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the development of computed tomography (CT) equipment and the increasing use of lung
      cancer screening programs with low-dose CT, a growing number of early-stage lung cancers were
      detected so that a large number of patients have undergone surgery.

      Although a number of radiological studies have been used morphological signs so-called
      semantic features to make a differential diagnosis, it is still hard to apply by clinician
      because pulmonary nodules especially ground-glass nodules and small size nodules have
      atypical radiology signs and have strong subjectivity from different observers. Recently,
      CT-based radiomics, extracting the quantitative high-throughput features from medical images
      and facilitating clinical decision-making system, showed a good performance to predict
      diagnosis and prognosis of diverse cancer.

      Therefore, the proposed project aims to develop and validate radiomics models based on CT
      images to identify malignant nodules and then to discriminate the different types of lung
      adenocarcinoma in patients with pulmonary nodules.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 11, 2018</start_date>
  <completion_date type="Actual">February 1, 2019</completion_date>
  <primary_completion_date type="Actual">January 11, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Malignant nodules classifier</measure>
    <time_frame>30 days</time_frame>
    <description>Model based on Radiomic that can differentiate malignant nodules from benign nodules.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Invasive adenocarcinoma classifier</measure>
    <time_frame>30 days</time_frame>
    <description>Model based on Radiomic that can differentiate invasive adenocarcinoma from non-invasive adenocarcinoma.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">800</enrollment>
  <condition>Lung Neoplasms</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Lung Diseases</condition>
  <condition>Neoplasms</condition>
  <condition>Pathology</condition>
  <arm_group>
    <arm_group_label>Training dataset</arm_group_label>
    <description>No interventions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>External validation1</arm_group_label>
    <description>No interventions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>External validation2</arm_group_label>
    <description>No interventions</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>radiomics</intervention_name>
    <description>The high-throughput extraction of large amounts of quantitative image features from medical images</description>
    <arm_group_label>External validation1</arm_group_label>
    <arm_group_label>External validation2</arm_group_label>
    <arm_group_label>Training dataset</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pulmonary nodules in the collaborating institutes.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  intraoperative frozen section diagnosis and final pathology diagnosis are available

          -  preoperative standard non-enhanced CT is available

          -  Pathologically confirmed

        Exclusion Criteria:

          -  with a previous history of radiation therapy, chemotherapy or biopsy

          -  the time interval between the CT examination and surgery was more than two weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Affiliated Zhongshan Hospital of Dalian University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>March 11, 2019</last_update_submitted>
  <last_update_submitted_qc>March 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>CT</keyword>
  <keyword>Frozen sections</keyword>
  <keyword>Radiomics</keyword>
  <keyword>Lung adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Multiple Pulmonary Nodules</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

